Compounds > 2,3-bis(3'-hydroxybenzyl)butyrolactone
Page last updated: 2024-09-02

2,3-bis(3'-hydroxybenzyl)butyrolactone and Prostatic Neoplasms

2,3-bis(3'-hydroxybenzyl)butyrolactone has been researched along with Prostatic Neoplasms in 19 studies

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's12 (63.16)29.6817
2010's7 (36.84)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bolvig, AK; Christensen, J; Eriksen, AK; Kyrø, C; Landberg, R; Nørskov, N; Olsen, A; Overvad, K; Tjønneland, A1
Adlercreutz, H; Bjartell, A; Drake, I; Gullberg, B; Olsson, H; Sonestedt, E; Tikkanen, MJ; Wallström, P; Wirfält, E1
Azrad, M; Brenner, DE; Demark-Wahnefried, W; Dewhirst, M; Madden, J; Moul, JW; Polascik, TJ; Ruffin, MT; Snyder, DC; Vollmer, RT1
McCann, MJ; Rowland, IR; Roy, NC2
Adlercreutz, H; Dillner, J; Gislefoss, R; Hakama, M; Hallmans, G; Langseth, H; Lumme, S; Luostarinen, T; Saikku, P; Stattin, P; Stenman, UH; Tenkanen, L; Tuohimaa, P1
Chen, LH; Demark-Wahnefried, W; Fang, J; Li, H; Lin, X; Sun, Z; Wu, Y1
Habib, FK; Halley, L; Ho, CK; Wei, J1
Arisaka, O; Evans, BA; Miyake, N; Morgan, LD; Morton, MS1
Adlercreutz, H; Albanes, D; Kilkkinen, A; Pietinen, P; Virtamo, J; Virtanen, MJ1
Adlercreutz, H; Auprich, M; Brössner, C; Fink, K; Madersbacher, S; Petritsch, K; Petritsch, P; Rehak, P1
Adlercreutz, H; Biessy, C; Bylund, A; Hallmans, G; Kaaks, R; Stattin, P1
Adami, HO; Adlercreutz, H; Andersson, SO; Bälter, KA; Bellocco, R; Chang, ET; Grönberg, H; Hedelin, M; Heinonen, SM; Johansson, JE; Klint, A1
Alexander, FE; Bolton-Smith, C; Heald, CL; Morton, MS; Ritchie, MR1
Chen, LH; Demark-Wahnefried, W; Fang, J; Li, H; Lin, X1
Adlercreutz, H2
Berrar, D; Gill, CI; Linton, T; McCann, MJ; McGlynn, H; Rowland, IR1
Adlercreutz, H; Dillner, J; Hakama, M; Hallmans, G; Harvei, S; Jellum, E; Lehtinen, M; Lumme, S; Luostarinen, T; Stattin, P; Stumpf, K; Tenkanen, L; Teppo, L1

Reviews

2 review(s) available for 2,3-bis(3'-hydroxybenzyl)butyrolactone and Prostatic Neoplasms

ArticleYear
Lignans and human health.
    Critical reviews in clinical laboratory sciences, 2007, Volume: 44, Issue:5-6

    Topics: 4-Butyrolactone; Animals; Cardiovascular Diseases; Colorectal Neoplasms; Dietary Fiber; Edible Grain; Endometrial Neoplasms; Feeding Behavior; Female; Health Status; Humans; Isoflavones; Lignans; Male; Phytoestrogens; Plants, Edible; Prostatic Neoplasms; Seeds; Vegetables

2007
Phyto-oestrogens and cancer.
    The Lancet. Oncology, 2002, Volume: 3, Issue:6

    Topics: 4-Butyrolactone; Animals; Breast Neoplasms; Diet; Estrogens, Non-Steroidal; Female; Glycine max; Humans; Isoflavones; Lignans; Male; Neoplasms; Phytoestrogens; Plant Preparations; Prostatic Neoplasms; Tumor Cells, Cultured

2002

Trials

1 trial(s) available for 2,3-bis(3'-hydroxybenzyl)butyrolactone and Prostatic Neoplasms

ArticleYear
Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer.
    Journal of medicinal food, 2013, Volume: 16, Issue:4

    Topics: 4-Butyrolactone; Aged; Antineoplastic Agents, Phytogenic; Biomarkers; Cell Proliferation; Dietary Supplements; Flax; Humans; Ki-67 Antigen; Lignans; Male; Middle Aged; Phytotherapy; Plant Extracts; Prostatic Neoplasms; Vascular Endothelial Growth Factor A

2013

Other Studies

16 other study(ies) available for 2,3-bis(3'-hydroxybenzyl)butyrolactone and Prostatic Neoplasms

ArticleYear
Prediagnostic enterolactone concentrations and mortality among Danish men diagnosed with prostate cancer.
    European journal of clinical nutrition, 2017, Volume: 71, Issue:10

    Topics: 4-Butyrolactone; Adult; Cohort Studies; Denmark; Diet; Early Detection of Cancer; Humans; Lignans; Male; Middle Aged; Proportional Hazards Models; Prostatic Neoplasms; Registries; Risk Factors; Survival Analysis; White People

2017
Plasma enterolactone and risk of prostate cancer in middle-aged Swedish men.
    European journal of nutrition, 2018, Volume: 57, Issue:7

    Topics: 4-Butyrolactone; Case-Control Studies; Humans; Life Style; Lignans; Male; Middle Aged; Prostatic Neoplasms; Risk Factors; Sweden

2018
The anti-proliferative effects of enterolactone in prostate cancer cells: evidence for the role of DNA licencing genes, mi-R106b cluster expression, and PTEN dosage.
    Nutrients, 2014, Nov-03, Volume: 6, Issue:11

    Topics: 4-Butyrolactone; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Lignans; Male; MicroRNAs; Mitochondria; Prostatic Neoplasms; PTEN Phosphohydrolase; RNA, Messenger

2014
Longitudinal biobanks-based study on the joint effects of infections, nutrition and hormones on risk of prostate cancer.
    Acta oncologica (Stockholm, Sweden), 2016, Volume: 55, Issue:7

    Topics: 4-Butyrolactone; Adult; Blood Banks; Case-Control Studies; Chlamydia Infections; Chlamydia trachomatis; Cohort Studies; Finland; Human papillomavirus 18; Humans; Lignans; Longitudinal Studies; Male; Middle Aged; Norway; Papillomavirus Infections; Prostatic Neoplasms; Risk Factors; Sweden; Testosterone; Vitamin D

2016
Enterolactone inhibits insulin-like growth factor-1 receptor signaling in human prostatic carcinoma PC-3 cells.
    The Journal of nutrition, 2009, Volume: 139, Issue:4

    Topics: 4-Butyrolactone; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor I; Lignans; Male; Phosphotyrosine; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Signal Transduction

2009
Analysis of prostate cancer association with four single-nucleotide polymorphisms from genome-wide studies and serum phyto-estrogen concentrations.
    Prostate cancer and prostatic diseases, 2012, Volume: 15, Issue:4

    Topics: 4-Butyrolactone; Aged; Alleles; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Lignans; Male; Middle Aged; Polymorphism, Single Nucleotide; Prostatic Neoplasms; Risk Factors; Scotland

2012
Anti-proliferative effects of physiological concentrations of enterolactone in models of prostate tumourigenesis.
    Molecular nutrition & food research, 2013, Volume: 57, Issue:2

    Topics: 4-Butyrolactone; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; DNA Replication; Humans; Lignans; Male; Mitochondria; Prostatic Neoplasms; Real-Time Polymerase Chain Reaction

2013
Phytoestrogen concentrations in serum from Japanese men and women over forty years of age.
    The Journal of nutrition, 2002, Volume: 132, Issue:10

    Topics: 4-Butyrolactone; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chromans; Diet; Equol; Estrogens, Non-Steroidal; Female; Gas Chromatography-Mass Spectrometry; Genistein; Humans; Isoflavones; Japan; Lignans; Male; Middle Aged; Phytoestrogens; Plant Preparations; Prostatic Neoplasms; United Kingdom

2002
Serum enterolactone concentration is not associated with prostate cancer risk in a nested case-control study.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2003, Volume: 12, Issue:11 Pt 1

    Topics: 4-Butyrolactone; Aged; Case-Control Studies; Fluoroimmunoassay; Humans; Lignans; Male; Middle Aged; Odds Ratio; Prostatic Neoplasms; Risk Factors

2003
Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases.
    Urology, 2004, Volume: 64, Issue:4

    Topics: 4-Butyrolactone; Adenocarcinoma; Aged; Aged, 80 and over; Diet; Genistein; Humans; Lignans; Male; Middle Aged; Organ Size; Phytoestrogens; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms

2004
Prospective study of plasma enterolactone and prostate cancer risk (Sweden).
    Cancer causes & control : CCC, 2004, Volume: 15, Issue:10

    Topics: 4-Butyrolactone; Cohort Studies; Humans; Life Style; Lignans; Male; Middle Aged; Obesity; Phytoestrogens; Prospective Studies; Prostatic Neoplasms; Risk; Smoking; Sweden

2004
Dietary phytoestrogen, serum enterolactone and risk of prostate cancer: the cancer prostate Sweden study (Sweden).
    Cancer causes & control : CCC, 2006, Volume: 17, Issue:2

    Topics: 4-Butyrolactone; Diet; Health Behavior; Humans; Life Style; Lignans; Male; Phytoestrogens; Prostatic Neoplasms; Risk Factors; Sweden

2006
Phyto-oestrogens and risk of prostate cancer in Scottish men.
    The British journal of nutrition, 2007, Volume: 98, Issue:2

    Topics: 4-Butyrolactone; Aged; Case-Control Studies; Diet; Diet Surveys; Energy Intake; Equol; Genistein; Humans; Isoflavones; Lignans; Male; Middle Aged; Phytoestrogens; Prostatic Neoplasms; Risk Assessment; Scotland

2007
Enterolactone induces apoptosis in human prostate carcinoma LNCaP cells via a mitochondrial-mediated, caspase-dependent pathway.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:9

    Topics: 4-Butyrolactone; Apoptosis; Caspases; Cell Survival; Cytochromes c; Enzyme Activation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Immunoblotting; In Situ Nick-End Labeling; Lignans; Male; Membrane Potential, Mitochondrial; Mitochondria; Phytoestrogens; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2007
Enterolactone restricts the proliferation of the LNCaP human prostate cancer cell line in vitro.
    Molecular nutrition & food research, 2008, Volume: 52, Issue:5

    Topics: 4-Butyrolactone; Cell Division; Cell Line, Tumor; Cell Survival; Humans; Lignans; Male; Mitochondria; Phytoestrogens; Polymerase Chain Reaction; Prostate-Specific Antigen; Prostatic Neoplasms

2008
Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study.
    International journal of cancer, 2002, May-01, Volume: 99, Issue:1

    Topics: 4-Butyrolactone; Case-Control Studies; Cohort Studies; Estrogens; Finland; Fluoroimmunoassay; Humans; Lignans; Male; Middle Aged; Norway; Prospective Studies; Prostatic Neoplasms; Risk Factors; Sweden

2002